The arrival of Retatrutide ZPHC, at a strength of 120mg, is generating considerable interest within the healthcare community. This groundbreaking dual GIP and GLP-1 agonist medication suggests to provide notable improvements in weight shedding compared to existing therapies. Initial patient data have shown significant declines in body fat percentag